ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $39,943,000 | -11.9% | 352,860 | +7.7% | 0.18% | -30.9% |
| Q4 2020 | $45,342,000 | +51.9% | 327,553 | -6.6% | 0.26% | +66.2% |
| Q3 2020 | $29,854,000 | +47.3% | 350,821 | +27.5% | 0.15% | +33.9% |
| Q2 2020 | $20,274,000 | -25.7% | 275,247 | -42.2% | 0.12% | -26.3% |
| Q3 2017 | $27,277,000 | -8.7% | 475,875 | -1.0% | 0.16% | -13.3% |
| Q2 2017 | $29,861,000 | +1.5% | 480,779 | +10.7% | 0.18% | -2.7% |
| Q1 2017 | $29,432,000 | -3.9% | 434,240 | -0.3% | 0.18% | -8.0% |
| Q4 2016 | $30,635,000 | -0.0% | 435,716 | +0.9% | 0.20% | -3.4% |
| Q3 2016 | $30,636,000 | +82.9% | 431,869 | +26.1% | 0.21% | +79.3% |
| Q2 2016 | $16,753,000 | -25.4% | 342,540 | -3.4% | 0.12% | -25.6% |
| Q1 2016 | $22,459,000 | -44.8% | 354,762 | -2.1% | 0.16% | -42.6% |
| Q4 2015 | $40,667,000 | -40.4% | 362,516 | -48.9% | 0.27% | +16.7% |
| Q3 2015 | $68,284,000 | – | 709,014 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iguana Healthcare Management, LLC | 75,000 | $5,084,000 | 2.52% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 1,237,825 | $83,900,000 | 1.18% |
| CAPITAL INTERNATIONAL LTD /CA/ | 206,718 | $14,011,000 | 0.91% |
| Cormorant Asset Management, LP | 75,000 | $5,084,000 | 0.74% |
| Capital International Sarl | 107,450 | $7,283,000 | 0.63% |
| Rock Springs Capital Management LP | 159,750 | $10,828,000 | 0.62% |
| Opus Point Partners Management, LLC | 12,201 | $827,000 | 0.61% |
| Hood River Capital Management LLC | 109,629 | $7,431,000 | 0.56% |
| Aureus Asset Management, LLC | 50,740 | $2,927,000 | 0.51% |
| ROCKEFELLER FINANCIAL SERVICES INC | 374,663 | $25,395,000 | 0.51% |